Packaging capacity of adeno-associated virus serotypes: impact of larger genomes on infectivity and postentry steps.
about
The therapeutic potential of genome editing for β-thalassemiaStructural Insights into Adeno-Associated Virus Serotype 5Mybpc3 gene therapy for neonatal cardiomyopathy enables long-term disease prevention in miceAdeno-associated virus serotype 9 efficiently targets ischemic skeletal muscle following systemic delivery.Imaging activity in astrocytes and neurons with genetically encoded calcium indicators following in utero electroporation.Myosin7a deficiency results in reduced retinal activity which is improved by gene therapy.Designer gene delivery vectors: molecular engineering and evolution of adeno-associated viral vectors for enhanced gene transferCharacterization of genome integrity for oversized recombinant AAV vector.Limitations of encapsidation of recombinant self-complementary adeno-associated viral genomes in different serotype capsids and their quantitationEffect of genome size on AAV vector packaging.Evidence for the failure of adeno-associated virus serotype 5 to package a viral genome > or = 8.2 kb.Optimized adeno-associated virus (AAV)-protein phosphatase-5 helper viruses for efficient liver transduction by single-stranded AAV vectors: therapeutic expression of factor IX at reduced vector doses.Viral vectors for neurotrophic factor delivery: a gene therapy approach for neurodegenerative diseases of the CNSThe potential of adeno-associated viral vectors for gene delivery to muscle tissue.Gene delivery with viral vectors for cerebrovascular diseases.Impact of ETIF deletion on safety and immunogenicity of equine herpesvirus type 1-vectored vaccines.Modular dispensability of dysferlin C2 domains reveals rational design for mini-dysferlin molecules.Proteasome inhibitors enhance gene delivery by AAV virus vectors expressing large genomes in hemophilia mouse and dog models: a strategy for broad clinical application.Efficient transgene reconstitution with hybrid dual AAV vectors carrying the minimized bridging sequencesVector platforms for gene therapy of inherited retinopathies.Cystic fibrosis transmembrane conductance regulator with a shortened R domain rescues the intestinal phenotype of CFTR-/- mice.Lentiviral gene replacement therapy of retinas in a mouse model for Usher syndrome type 1B.Efficacy and safety of long-term prophylaxis in severe hemophilia A dogs following liver gene therapy using AAV vectors.A simple method to increase the transduction efficiency of single-stranded adeno-associated virus vectors in vitro and in vivo.Subretinal gene delivery using helper-dependent adenoviral vectors.Recombinant AAV-directed gene therapy for type I glycogen storage diseases.Bioengineered coagulation factor VIII enables long-term correction of murine hemophilia A following liver-directed adeno-associated viral vector delivery.Gene Therapy of ABCA4-Associated Diseases.Gene Therapy for the Retinal Degeneration of Usher Syndrome Caused by Mutations in MYO7ALarge-scale production of lentiviral vector in a closed system hollow fiber bioreactor.Targeted genetic manipulations of neuronal subtypes using promoter-specific combinatorial AAVs in wild-type animalsIdentification and Validation of Small Molecules That Enhance Recombinant Adeno-associated Virus Transduction following High-Throughput Screens.In vivo gene transfer strategies to achieve partial correction of von Willebrand disease.Dysferlin and animal models for dysferlinopathycis effects in adeno-associated virus type 2 replication.Gene therapy of inherited retinopathies: a long and successful road from viral vectors to patients.Novel Mutant AAV2 Rep Proteins Support AAV2 Replication without Blocking HSV-1 Helpervirus ReplicationRetinal Gene Therapy: Current Progress and Future Prospects.Serotype-dependent packaging of large genes in adeno-associated viral vectors results in effective gene delivery in mice.In vitro analysis of promoter activity in Müller cells
P2860
Q26766232-C3422F3D-AFAC-4F04-BFA6-8B634CA3D0ACQ27679454-C9129C6E-38B5-475D-BD86-3C0AD416F45BQ28253008-0957CD91-BEBF-4516-963B-1242B0577649Q30414524-837A9511-C3F9-45CA-B49B-556061E4E439Q30640176-150FF3BD-1AF8-4E74-88EE-036756216173Q31132177-40DF9D83-880D-4577-BE1C-27FA531A4108Q33296224-E2C60521-50C0-4DAB-A5D7-EBB419E5D088Q33576852-331CAE66-15B4-4F35-9A4E-D173F07D421CQ33586309-B14ED30C-4EEB-4B20-B89F-EB14AE734BA4Q33730405-62A4F901-2482-46F1-AB21-E660C89C627CQ33730469-D2510A5E-467E-4487-91A4-42C84D15ECD5Q33832799-58588EFB-8A69-49AD-952B-65B78C09A898Q33894621-CB76523F-908C-4AB6-9057-08D5294B1FEBQ33902499-4EFFA2DD-08EB-412E-84AE-400F4DA23FDFQ33917592-CBBDE949-8006-4636-BE4A-A5F01DDA0FA9Q34296144-943C147D-F0C3-4AA2-8C05-6E93A99EE8D6Q34318021-7C911042-C57B-4306-89C8-9F78E0CC798EQ34343763-783710C9-D401-4436-A28B-89334837F2FBQ34511733-0E78B4A5-DFA5-42A1-B3E2-3D967AD3E25DQ34561531-EC2B4C3A-BAB7-4A90-B3B5-9E7BC426B928Q34582621-229F3E3C-2DAE-4066-9F58-70DCFF420578Q34608354-007E9B32-65B9-4F35-938F-9F28A9EDA067Q34621668-978EE8F3-7075-4E18-BD3E-8E25BBA1E9BFQ34843762-9433CE8B-7819-445B-A42F-AB6DD2CF6075Q35073956-8D5A9881-4426-4D77-A960-97D179E394DCQ35078590-B8E6BF93-573F-41F7-87A8-C76DBF261148Q35184180-193C70C5-2000-4478-8430-A72D1878D9C5Q35663857-7E40DCC5-8960-4D6E-BFC9-C26AABD8805BQ35664199-F3531CB1-C048-48A0-BE35-B52F23B38EBBQ35751032-547BE8E6-69F3-4B34-8D2D-08667302C332Q35808747-B3C7E379-DA5A-48D3-8996-878391D20938Q36009041-57F56A51-50E7-4488-AD53-6776D8141D6FQ36084450-E25E3EE1-2528-4D32-A3DB-5967D9A4A31EQ36085192-70D686EA-EF57-4A72-9A36-8B37C47BCD25Q36098985-022ADEE7-6E42-422C-BEC2-6E4470519F1AQ36147481-CCCB9006-B8C3-497F-9EFA-E36CA18EA201Q36261377-A7E2899D-2AC4-40D1-9673-A7089657252EQ36306263-2CAB8681-C4E5-4871-A2D0-D3DBC05A26A1Q36545533-617361C1-D6A3-4B85-AB2F-4D5A95BA046AQ36580252-4ED2205E-81C0-4C9E-942E-1D1DD0D69462
P2860
Packaging capacity of adeno-associated virus serotypes: impact of larger genomes on infectivity and postentry steps.
description
2005 nî lūn-bûn
@nan
2005 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2005 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
name
Packaging capacity of adeno-as ...... nfectivity and postentry steps
@nl
Packaging capacity of adeno-as ...... fectivity and postentry steps.
@ast
Packaging capacity of adeno-as ...... fectivity and postentry steps.
@en
Packaging capacity of adeno-as ...... fectivity and postentry steps.
@en-gb
type
label
Packaging capacity of adeno-as ...... nfectivity and postentry steps
@nl
Packaging capacity of adeno-as ...... fectivity and postentry steps.
@ast
Packaging capacity of adeno-as ...... fectivity and postentry steps.
@en
Packaging capacity of adeno-as ...... fectivity and postentry steps.
@en-gb
prefLabel
Packaging capacity of adeno-as ...... nfectivity and postentry steps
@nl
Packaging capacity of adeno-as ...... fectivity and postentry steps.
@ast
Packaging capacity of adeno-as ...... fectivity and postentry steps.
@en
Packaging capacity of adeno-as ...... fectivity and postentry steps.
@en-gb
P2860
P1433
P1476
Packaging capacity of adeno-as ...... fectivity and postentry steps.
@en
P2093
Joshua C Grieger
Richard J Samulski
P2860
P304
P356
10.1128/JVI.79.15.9933-9944.2005
P407
P577
2005-08-01T00:00:00Z